Alnylam Pharmaceuticals, Inc. (OQ:ALNY)

Business Focus: Biotechnology & Medical Research

Apr 18, 2024 07:25 am ET
ALNY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 17, 2024 07:25 am ET
Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY
NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 11, 2024 07:20 am ET
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 10, 2024 07:25 am ET
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 09, 2024 07:30 am ET
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 08, 2024 07:20 am ET
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY
NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Apr 07, 2024 08:00 am ET
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamid
Mar 29, 2024 07:20 am ET
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 28, 2024 07:30 am ET
Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY
NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 26, 2024 07:20 am ET
Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 25, 2024 07:30 am ET
Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 22, 2024 07:20 am ET
Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALNY
NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 21, 2024 07:20 am ET
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ALNY
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 20, 2024 08:00 am ET
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, a
Mar 20, 2024 07:30 am ET
ALNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Alnylam Pharmaceuticals, Inc. Investment
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 19, 2024 07:25 am ET
ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 14, 2024 04:30 pm ET
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 13, 2024 07:30 am ET
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the
Mar 13, 2024 07:25 am ET
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 11, 2024 08:00 pm ET
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 11, 2024 07:25 am ET
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 09, 2024 07:01 pm ET
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / March 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 07, 2024 04:15 pm ET
Alnylam Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ALNY
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 07, 2024 04:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Mar 07, 2024 07:30 am ET
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 06, 2024 07:25 am ET
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 05, 2024 07:30 am ET
Alnylam Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alnylam (ALNY)
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 05, 2024 07:30 am ET
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, met the primary endpoint showing that zilebesiran resu
Mar 03, 2024 12:00 pm ET
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / March 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 03, 2024 11:13 am ET
Levi & Korsinsky Reminds Shareholders of an Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / March 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 02, 2024 09:01 pm ET
Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Mar 02, 2024 08:01 pm ET
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / March 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Feb 28, 2024 03:30 pm ET
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Feb 28, 2024 03:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Feb 28, 2024 10:00 am ET
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Feb 27, 2024 08:30 am ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Feb 26, 2024 04:40 pm ET
ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / February 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Feb 21, 2024 01:45 pm ET
ALNY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws.
Feb 15, 2024 08:00 am ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2023 and reviewed recent business highlights.
Jan 29, 2024 08:00 am ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2023 on Thursday, February 15, 2024, before the U.S. financial markets open.
Jan 09, 2024 08:05 am ET
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at the J.P. Morgan Healthcare Conference in San Franc
Jan 07, 2024 06:00 pm ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.
Jan 02, 2024 07:30 am ET
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Fran
Dec 13, 2023 07:30 am ET
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four RNAi therapeutic products
Dec 06, 2023 08:00 am ET
Alnylam to Webcast Virtual R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website,
Nov 30, 2023 08:00 am ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees).
Nov 13, 2023 06:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 09, 2023 12:43 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Nov 07, 2023 03:36 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws
Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities...
Nov 07, 2023 08:00 am ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Nov 06, 2023 12:28 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Nov 05, 2023 03:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 03, 2023 06:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 02, 2023 12:34 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)
The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.: On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC)...
Nov 02, 2023 08:00 am ET
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
“We continued to deliver strong commercial results in the third quarter, with the successful launch of AMVUTTRA contributing to 35% year-over-year growth in net product revenues,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “While we were disappointed by the recent Complete Response Letter for ONPATTRO for the treatment of the cardiomyopathy of ATTR amyloidosis, we remain confident in the HELIOS-B Phase 3 study of vutrisiran, which is on track to deliver topline results in early 2024. We’re also excited about advancements across our broad pipeline of RNAi therapeutics,
Nov 01, 2023 12:39 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Oct 31, 2023 12:50 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws
Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential...
Oct 30, 2023 01:08 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)
The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.: On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC)...
Oct 27, 2023 02:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Oct 27, 2023 01:19 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Oct 26, 2023 02:00 pm ET
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its third place ranking in Science magazine’s Top Employer Survey for 2023. This marks the fifth year that Alnylam was featured as one of the top three companies in the annual survey of more than 6,800 professionals across biotechnology, b
Oct 26, 2023 12:47 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws
Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities...
Oct 25, 2023 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 25, 2023 05:19 pm ET
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were published
Oct 25, 2023 12:57 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)
The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.: On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC)...
Oct 25, 2023 11:05 am ET
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy
Oct 23, 2023 12:40 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Oct 20, 2023 12:48 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)
The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.: On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC)...
Oct 19, 2023 03:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Oct 19, 2023 01:13 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S....
Oct 19, 2023 08:00 am ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial markets open.
Oct 17, 2023 06:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 17, 2023 06:06 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.
Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam...
Oct 09, 2023 07:30 am ET
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-me
Oct 06, 2023 07:00 am ET
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of Am
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (H
Sep 13, 2023 04:57 pm ET
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the positive outcome of the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi thera
Sep 13, 2023 07:00 am ET
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock.
Sep 07, 2023 07:00 am ET
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovas
Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, met the primary endpoint demonstrating a dose-dependent, cl
Sep 06, 2023 03:00 am ET
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also known as hATTR or ATTRv*. The recommendations, published in the BMJ Open,1
Aug 25, 2023 05:00 pm ET
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna for patent infringement. To date, in two separate
Aug 03, 2023 08:00 am ET
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
Aug 02, 2023 08:30 am ET
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston.
Jul 24, 2023 01:00 am ET
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development. The partnership a
Jul 20, 2023 08:00 am ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open.
Jul 19, 2023 05:00 pm ET
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from its Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medici
Jul 17, 2023 02:21 am ET
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (C
Jun 30, 2023 09:00 am ET
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigati
Jun 05, 2023 04:00 pm ET
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00 am ET) at the Waldorf Astoria Monarch Beach Resort & Club in Dana Poin
May 20, 2023 10:50 am ET
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediat
May 04, 2023 08:00 am ET
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
May 03, 2023 04:00 pm ET
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas.
May 03, 2023 08:00 am ET
Alnylam Issues 2022 Corporate Responsibility Report
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its
Apr 26, 2023 04:05 pm ET
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s d
Apr 26, 2023 04:05 pm ET
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi...
Apr 20, 2023 08:00 am ET
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.
Mar 09, 2023 06:00 am ET
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland, March 9, 2023 /CNW/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. 
Mar 09, 2023 06:00 am ET
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. 
Mar 08, 2023 07:00 am ET
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.
Mar 01, 2023 08:00 am ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Feb 23, 2023 08:00 am ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.
Feb 21, 2023 08:00 am ET
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of
Feb 02, 2023 08:00 am ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.
Jan 08, 2023 06:00 pm ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.
Jan 05, 2023 04:00 pm ET
Alnylam Announces Updates to its Board of Directors
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, today announces appointment of Carolyn Bertozzi, Ph.D. a Nobel Laureate to the Board. Dr. Bertozzi is known is known for her work in chemical biology. She is a pioneer for emerging technology and has founded ten biopharmaceutical companies and guided mor
Jan 03, 2023 04:00 pm ET
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Fran
Dec 21, 2022 08:00 am ET
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase (KHK) for the treatme
Dec 15, 2022 08:00 am ET
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four RNAi therapeutic products, a
Dec 08, 2022 04:00 pm ET
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidos
Dec 08, 2022 07:00 am ET
Alnylam to Webcast Virtual R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website,
Dec 01, 2022 07:00 am ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the “Largest Employer” category. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer category (> 1,000 employees).
Nov 09, 2022 08:00 am ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Oct 27, 2022 02:00 pm ET
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazine’s 2022 Top Employer Survey. This marks the fourth year Alnylam was featured as one of the top three companies in the annual survey of more than 6,200 professionals across biotechnology, biopharmaceutic
Oct 27, 2022 08:00 am ET
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights.
Oct 13, 2022 08:00 am ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.
Oct 06, 2022 08:30 pm ET
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH
Sep 30, 2022 02:00 pm ET
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the
Sep 21, 2022 04:00 pm ET
Alnylam Announces New Management Appointments
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer (CECO), and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer (CDSO). Both executives
Sep 20, 2022 07:00 am ET
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for AMVUTTRA® (vutrisiran), an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or st
Sep 19, 2022 08:00 am ET
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer presentations from Alnylam scientists and program leaders who will review recent progress in a selection of th
Sep 15, 2022 07:00 am ET
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).
Sep 15, 2022 07:00 am ET
Sep 13, 2022 08:00 am ET
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during an
Sep 13, 2022 06:00 am ET
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers
Sep 12, 2022 06:45 am ET
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A
Sep 08, 2022 02:30 am ET
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were presented today in a
Sep 06, 2022 08:00 am ET
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 11:10 am ET at the Sheraton New York Hotel.
Aug 29, 2022 08:00 am ET
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgA
Aug 24, 2022 04:00 pm ET
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades of senior leadership and board experience at biopharmaceutical companies. He served as Chief Scientific Officer and President of R&D for B
Aug 18, 2022 07:30 am ET
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during a late-breake
Aug 11, 2022 10:01 am ET
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced the appointments of John M. Maraganore, Ph.D. and...
Aug 03, 2022 09:41 am ET
Thinking about trading options or stock in Apple, Alnylam Pharmaceuticals, Atlas Air Worldwide, Alteryx, or Chevron?
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, ALNY, AAWW, AYX, and CVX.
Aug 03, 2022 07:00 am ET
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the
Aug 02, 2022 08:00 am ET
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of
Jul 28, 2022 08:00 am ET
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2022 and reviewed recent business highlights.
Jul 27, 2022 08:00 am ET
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and collaborators have identified mutations in the INHBE gene associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20 percent of adults worldwide. The discover
Jul 18, 2022 08:00 am ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.
Jun 13, 2022 07:22 pm ET
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA™ (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary tran
Jun 09, 2022 07:00 am ET
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in development in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy (IgAN). At Week
Jun 02, 2022 04:00 pm ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Jun 02, 2022 11:42 am ET
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that data from its preclinical research on delivery of lipophilic short interfering RNA (siRNA) conjugates to extra-hepatic tissues, including the central nervous system (CNS), were published online in Nature Biotechnology. The publi
May 24, 2022 07:00 am ET
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from the six-month primary analysis period of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being
May 23, 2022 07:00 am ET
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidos
May 18, 2022 08:00 am ET
Alnylam Announces Health Canada Authorization of OXLUMO™ (lumasiran), the First and Only Treatment for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Paediatric and Adult Patients
Authorization Based on two Pivotal Phase III trials, ILLUMINATE-A and ILLUMINATE-B; Showing Significant Reduction in Urinary Oxalate which Drives the Progression of PH1 Disease  
May 04, 2022 08:00 am ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Apr 28, 2022 08:00 am ET
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
“The first quarter of 2022 saw a steady increase in patients on therapy across all products in our commercial portfolio, despite combined product revenues that were down compared to Q4 2021, as anticipated, given several non-recurring revenue benefits in the fourth quarter of 2021, as well as some pandemic-related impact experienced early in the quarter. We continue to make progress with our pipeline programs, including our TTR franchise, for which we reported positive 18-month results from the HELIOS-A study of vutrisiran, and we remain on track for topline results from the APOLLO-B study of
Apr 14, 2022 08:30 am ET
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2022 on Thursday, April 28, 2022, before the U.S. financial markets open.
Apr 05, 2022 04:00 pm ET
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective April 16, 2022.
Apr 04, 2022 07:30 am ET
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of the New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloido
Mar 22, 2022 08:00 am ET
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2022 CNS Days, being held virtually, on Monday, March 28, 2022 at 2:00 pm ET
Mar 17, 2022 07:30 am ET
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
Alnylam is seeking fair compensation for use of its technology based on patent claims to a broad class of biodegradable lipids invented over a decade ago resulting from extensive research and investment. The Company is proud that this work has supported rapid development of the life-saving vaccines. Alnylam does not intend to seek an injunction or take action that impedes production, sale or distribution of the vaccines.
Mar 16, 2022 07:30 am ET
Alnylam Issues 2021 Corporate Responsibility Report
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its
Mar 01, 2022 07:00 am ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxi
Feb 28, 2022 04:00 pm ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Feb 28, 2022 07:00 am ET
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today on Rare Disease Day announced the premiere of its new documentary, Two of Me: Living with Porphyria, a film chronicling the lives of seven people around the world living with acute hepatic porphyria (AHP), a family of debilitating, rare gen
Feb 10, 2022 08:00 am ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2021 and reviewed recent business highlights.
Feb 08, 2022 08:30 am ET
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually, on Thursday, February 17, 2022 at 10:00 am ET.
Jan 24, 2022 08:38 am ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on Thursday, February 10, 2022, before the U.S. financial markets open.
Jan 21, 2022 07:30 am ET
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR a
Jan 14, 2022 07:00 am ET
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) a
Jan 09, 2022 01:00 pm ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.
Jan 06, 2022 07:30 am ET
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a collaboration with Novartis to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promo
Jan 04, 2022 07:30 am ET
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined Alnylam in 2006 as Vice President, Clinical Research with roles of increasing responsibility, ultimately serving as President of Research and Development (
Jan 03, 2022 07:00 am ET
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Monday, January 10, 2022 at 9:45 am ET. This presentation will include an update on unaudited fourt
Dec 22, 2021 04:23 pm ET
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Leqvio® (inclisiran), the fourth small interfering RNA (siRNA) therapy (or RNAi therapeutic) approved in the U.S., and the first and only to lower l
Dec 22, 2021 07:00 am ET
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeu
Dec 21, 2021 04:30 pm ET
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its third annual Patient Access Philosophy Report. This report is designed to measure Alnylam’s global progress against its 2017 commitments to ensuring broad access to RNAi therapeutics for people who may benefit.
Dec 20, 2021 04:00 pm ET
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the company has initiated a global Phase 2 study to evaluate the safety and efficacy of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in patients with recur
Dec 20, 2021 07:00 am ET
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1/2 study of ALN-XDH, an investigational RNAi therap
Dec 14, 2021 07:00 am ET
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluri
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and Type II Filing Variation to the European Medicines Agency (EMA) for lumasiran, an investigational RNAi therapeutic targeting hyd
Dec 09, 2021 07:41 am ET
Direxion Launches mRNA ETF (MSGR)
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.
Dec 02, 2021 08:00 am ET
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe’s 2021 Top Places to Work in the “Largest Employer” category. This is the seventh consecutive year that Alnylam has been named a Top Place to Work by the Boston Globe and the first year that Alnylam ha
Nov 23, 2021 08:00 am ET
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
Nov 19, 2021 07:00 am ET
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress, including its product and pipeline goals for 2022, focused on continued commercial execution of four RNAi therapeutic products, the potential launch of
Nov 13, 2021 08:00 am ET
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive interim results from the ongoing Phase 1 study of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hype
Nov 12, 2021 08:00 am ET
Alnylam to Webcast Virtual R&D Day
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website,
Nov 08, 2021 07:00 am ET
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in developmen
Nov 05, 2021 01:30 pm ET
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran, an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – that is being inves
Nov 01, 2021 04:00 pm ET
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science’s 2021 Top Employers Survey. The magazine’s annual survey of more than 7,200 people in biotechnology, biopharmaceutical, pharmaceutical, and related industries determine the top 20 best employer
Oct 28, 2021 08:00 am ET
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2021 and reviewed recent business highlights.
Oct 28, 2021 07:55 am ET
Alnylam Announces Planned CEO Leadership Transition
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021. Dr. Maraganore joined Alnylam in 2002 as the company’s founding CEO and has led the company’s advancement of RNAi therapeutics as a who
Oct 27, 2021 04:00 pm ET
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis, met all secondary endpoints
Oct 18, 2021 08:00 am ET
Oct 14, 2021 08:00 am ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open.
Oct 13, 2021 07:30 am ET
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity. Through this pr
Sep 29, 2021 07:30 am ET
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
Sep 28, 2021 04:00 pm ET
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET.
Sep 28, 2021 08:00 am ET
ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR)
ONPATTRO is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life measurements in patients with hATTR amyloidosis (relative to baseline)1, 2
Sep 13, 2021 07:00 am ET
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult pat
Sep 07, 2021 07:00 am ET
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis. Dat
Sep 01, 2021 04:00 pm ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
Aug 09, 2021 07:00 am ET
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis.
Aug 03, 2021 08:00 am ET
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2021 and reviewed recent business highlights.
Jul 29, 2021 07:00 am ET
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function. Lumasiran is an RNAi therap
Jul 21, 2021 08:00 am ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open.
Jul 19, 2021 09:31 am ET
Thinking about trading options or stock in Alnylam Pharmaceuticals, Tesla, Cintas, GameStop, or Microsoft?
NEW YORK, July 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALNY, TSLA, CTAS, GME, and MSFT.
Jun 30, 2021 07:00 am ET
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-BEE-siran” and formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angi
Jun 24, 2021 07:00 am ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATT
Jun 23, 2021 07:00 am ET
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer a range of presentations from Alnylam scientists and program leaders who will review recent progress in many o

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.